FY 2020 Notable Partnerships

- Immatics Biotechnologies GmbH, headquartered in Tubingen, Germany, and its Houston-based U.S. subsidiary, **Immatics US, Inc.**, initiated a strategic collaboration and option agreement with Celgene to develop novel adoptive cell therapies. The agreement announced August 28, 2019, grants Celgene with opt-in rights to assume responsibility for future worldwide development, manufacturing and commercialization of the lead candidates that are currently in development by Immatics. Under the terms of the agreement, Immatics will receive an upfront payment of $75 million for three programs exclusively optioned by Celgene and may be eligible to receive up to $505 million for each licensed product in option exercise payments, product development, regulatory and commercial milestone payments as well as tiered royalty payments on net sales.

  In February 2020, the company negotiated a strategic collaboration with GlaxoSmithKline to develop novel adoptive cell therapies targeting multiple cancer indications. The companies will collaborate on the identification, research and development of next-generation T-Cell Receptor Therapeutics with a focus on solid tumors. The parties will initially develop autologous T-cell therapies with the option to add allogeneic cell therapies using Immatics' ACTallo approach. Under the terms of the agreement, Immatics will receive an upfront payment of about $50 million for two initial programs and is eligible to receive over $550 million in development, regulatory and commercial milestone payments for each product as well as additional royalty payments.

  Immatics extends its cell therapy manufacturing collaboration with The University of Texas Health Science Center at Houston. The continued collaboration, announced in August 2020, grants Immatics access to UTHealth's state-of-the-art cGMP manufacturing infrastructure at the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory, enabling continued production and supply of Immatics' specialized, cell-based product candidates for testing in multiple clinical trials. Houston-based Immatics US received a $19.7 million CPRIT Product Development award in 2015 (DP150029) to develop personalized cellular therapies targeting multiple cancer types.

- **Salarius Pharmaceuticals, Inc.**, a Houston-based company, launched a collaborative partnership with the Ivy Brain Tumor Center at the Barrow Neurological Institute. CPRIT approved Product Development award DP160014 in 2016 totaling up to $18.7 million to develop and test Seclidemstat in a Phase 1 study for refractory or relapsed Ewing sarcoma. Ewing sarcoma is a rare and deadly pediatric bone cancer for which

there are no approved targeted treatments. The U.S. Food and Drug Administration granted Seclidemstat a Fast-Track Designation, as well as Orphan and Rare Pediatric Disease Designations, in recognition of the high unmet medical need facing Ewing's sarcoma patients. At the FDA's invitation, the company also presented Seclidemstat information at the June 17, 2020, public advisory committee meeting of the Pediatric Oncology Subcommittee. The collaboration with the Ivy Brain Tumor Center, announced August 26, 2019, will test Salarius' lead investigational compound, Seclidemstat, for the treatment of glioblastoma.

- In September 2019, IQ Global acquired an anti-cancer drug platform developed by researchers at The University of Texas at Austin, including Chemistry Professor **Jonathan Sessler, Ph.D.** IQ Global, an Australian-based biotechnology company, will use the TEX-Core drug platform to develop MRI-detectable treatments targeting drug-sensitive and drug-resistant cancers with platinum-based chemotherapy. Dr. Sessler received two CPRIT grants (RP140108, DP150087) totaling $3.7 million to support the development of TEX-Core and oxaliTEX, a therapeutic designed to treat platinum resistant ovarian cancer. OxaliTEX is the first drug planned for development from the platform.

- **Molecular Templates, Inc.** entered a strategic collaboration with Boston-based Vertex Pharmaceuticals, Inc. to discover and develop novel therapies to enhance the hematopoietic stem cell transplant process. The collaboration, announced November 18, 2019, aims to discover a new conditioning regimen utilizing Molecular Templates' engineered toxin antibody platform, which the company designed to target and remove specific cells to enable engraftment of new cells. Vertex will make a $38 million upfront payment to Molecular Templates, including an equity investment. Molecular Templates is also eligible to receive future development, regulatory and sales milestones and options payments of up to $522 million (across two targets) and tiered royalty payments on future sales.

  Headquartered in Austin, Molecular Templates received two CPRIT Product Development awards, including $10.6 million in 2011 (CC121020) to develop a novel treatment for Non-Hodgkin Lymphoma and $15.2 million in 2016 (DP160071) to develop a novel drug targeting multiple myeloma.

- **Hummingbird Bioscience, Inc.** signed an agreement with Mycenax Biotech in February 2020 to produce material for the Phase 1 clinical trial of its HMBD-002 program, which the Houston-based company plans to start in the second half of 2020. The company received a $13.1 million CPRIT Product Development award in

2019 (DP190027) to develop a monoclonal antibody therapy designed to reverse one of the main causes of resistance to immunotherapy drugs.

- **Allterum Therapeutics** announced a manufacturing scale-up partnership with Fujifilm Diosynth Biotechnologies. The partnership, reported in April 2020, supports manufacturing Allterum's antibody therapy in preclinical development to treat pediatric patients suffering from T-cell acute lymphoblastic leukemia (T-ALL). Houston-based Allterum received a $2.9 million CPRIT Seed award in 2019 (DP190025) to support development of the company's lead drug candidate. Fujifilm Diosynth USA , a global contract development and manufacturing organization, acquired Kalon Biotherapeutics in 2014. CPRIT awarded College Station-based Kalon a $7.9 million Product Development award in 2012 (CP120038) to support novel process developments for the manufacturing of cancer drugs. The College Station manufacturing facility is one of four biologics manufacturing locations operated by Fujifilm Diosynth.

- **NanoTx Therapeutics** licensed multiple rare cancer drug candidates to Plus Therapeutics, Inc. in May 2020. Plus Therapeutics made an upfront payment of $400,000 and $300,000 in voting stock and may pay up to $136.5 million in development and sales milestone payments as well as a tiered single-digit royalty on U.S. and European sales. San-Antonio-based NanoTx received a $2 million CPRIT Product Development award in 2015 (DP150021) to support the development of rhenium nanoliposomes for cancer radiation therapy.

- **Asylia Therapeutics** finalized an exclusive worldwide license agreement in May 2020 with The University of Texas M.D. Anderson Cancer Center to develop first-in-class immune modulating therapies for cancer, autoimmune and infectious diseases. The license covers a set of antibodies targeting epitopes on the extracellular or cell surface forms of heat-shock protein 70, including lead product ASY-77A, which scientists designed to enhance antigen presentation and trigger antitumor immune responses. Houston-based Asylia received a $3 million CPRIT SEED Product Development award in February 2020 (DP200033) to develop their lead compound, ASY-77A.

- **Perimeter Medical Imaging** expanded its ATLAS AI Project in July 2020 with the installation of the company's proprietary ultra-high resolution imaging platform at The University of Texas M.D. Anderson Cancer Center. The ATLAS AI Project allows Perimeter to collaborate with industry-leading cancer care centers, including The University of Texas Southwestern Medical Center, Baylor College of Medicine, and The University of Texas Health Science Center at San Antonio, which will use the

company’s OTIS device to collect images of breast tumors from approximately 400 patients to train and test Perimeter's ImgAssist AI technology. Perimeter designed this technology, which is currently under development, to use a machine learning model to help surgeons identify, in real-time, if cancer is still present when performing breast-conserving lumpectomy surgeries. Dallas-based Perimeter received a $7.4 CPRIT Product Development award in August 2019 (DP190087) to support this study.